Abstract:Objective: The study aimed to evaluate the effects of inhaled iloprost on oxygenation indices in neonates with persistent pulmonary hypertension of the newborn (PPHN). Study design: We conducted a retrospective chart review of 30 patients with PPHN from January 2014 to November 2018, who did not respond to inhaled nitric oxide (iNO) alone and received inhaled iloprost. Twenty-two patients met the inclusion criteria and eight patients were excluded from the study (complex cardiac disease and extreme prematurity). Patients were categorized as responders or nonresponders (patients who required extracorporeal membrane oxygenation or died). Oxygenation index, mean airway pressure (MAP), and arterial partial pressure of oxygen (PaO2) were recorded. Results: Among a total of 22 patients who were included in the study, 10 were classified as nonresponders as they required either extracorporeal membrane oxygenation or died. Gestational age and gender did not differ between responders and nonresponders. The median PaO2 was lower (37 vs. 42 mm Hg; p < 0.05) and median MAP was higher (20 vs. 17 cm H2O; p < 0.02) in nonresponders compared with responders just prior to initiating iloprost. Iloprost responders had a significant increase in median PaO2 and decrease in median oxygenation index in the 24 hours after initiating treatment (p < 0.05), with no significant change in required mean airway pressure over that same period. There was no change in vasopressor use or clinically significant worsening of platelets count, liver, and kidney functions after initiating iloprost. Conclusion: Inhaled iloprost is well tolerated and seems to have beneficial effects in improving oxygenation indices in neonates with PPHN who do not respond to iNO. There is a need of well-designed prospective trials to further ascertain the benefits of using inhaled iloprost as an adjunct treatment in neonates with PPHN who do not respond to iNO alone. Key points: · Inhaled iloprost seems to have beneficial effects in improving oxygenation indices in PPHN.. · Inhaled iloprost is generally well tolerated in newborns with PPHN.. · There is a need for prospective randomized controlled trials to further ascertain the benefits of using inhaled iloprost..

Inhaled Iloprost as a Rescue Therapy for Transposition of the Great Arteries With Persistent Pulmonary Hypertension of the Newborn

Prostaglandin E1 used as a pre-operative treatment for the neonates with transposition of great vessels with intact ventricular septum

Inhaled Nitric Oxide in Preterm and Term Neonates with Hypoxemic Respiratory Failure and Persistent Pulmonary Hypertension

Inhaled nitric oxide as a rescue therapy in a preterm neonate with severe pulmonary hypertension: a case report

A case of persistent pulmonary hypertension of the newborn: Treatment with inhaled iloprost

[Inhaled nitric oxide: a physiologic treatment of persistent pulmonary arterial hypertension in the newborn]

Successful Management of the Persistent Pulmonary Hypertension of the Newborn with Transposition of the Great Arteries by Restricted Patency of the Ductus Arteriosus: A Simple and Rational Novel Strategy

Persistent Pulmonary Hypertension of the Newborn with D-transposition of the Great Arteries: Management and Prognosis

Inhaled iloprost is an effective alternative therapy for persistent pulmonary hypertension in newborns

Treprostinil for persistent pulmonary hypertension of the newborn, with early onset sepsis in preterm infant: 2 Case reports

Effects of Inhaled Iloprost for the Management of Persistent Pulmonary Hypertension of the Newborn

Persistent pulmonary hypertension of the newborn: therapeutical approach.

Pulmonary vasodilator strategies in neonates with acute hypoxemic respiratory failure and pulmonary hypertension

Prostaglandin‐E1 infusion in persistent pulmonary hypertension of the newborn

Noninvasive inhaled nitric oxide for persistent pulmonary hypertension of the newborn: A single center experience

The use of Sildenafil in the Treatment of Persistent Pulmonary Hypertension of the Newborn: A Review of the Literature

Pulmonary Vasodilator Therapy in Persistent Pulmonary Hypertension of the Newborn

Pharmacologic strategies in neonatal pulmonary hypertension other than nitric oxide

Inhaled Nitric Oxide and Persistent Pulmonary Hypertension of the Newborn

Comparison of Inhaled Nitric Oxide and Iloprost in Infants with Moderate or Severe Pulmonary Hypertension Af-Ter Cardiac Surgery:A Prospective Randomized Trial

Inhaled nitric oxide in the treatment of moderate persistent pulmonary hypertension of the newborn: a randomized controlled, multicenter trial